Drug Trial Radar · NCT01433497
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Apr 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
656
Actual
Start
Aug 2011
Primary completion
Sep 2019
Study completion Feb 2020
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Sep 14, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis.
Conditions
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Relapse Free
Interventions
MasitinibDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- EDSSTime frame: 96 weeks
Locations
8 sites in 7 countries. Site status is shown where the registry gives one.
"St. Ivan Rilski" University Multiprofile Hospital for Active Treatment
Sofia, Bulgaria
GHICL hopital ST vincent de Paul
Lille, France
Hôpital de Gui de Chauliac
Montpellier, France
Universitätsklinikum Gießen und Marburg
Marburg, Germany
Rehibilitation Center "KENTAVROS"
Volos, Greece
KO-MED Centra Kliniczne Lublin II
Lublin, Poland
Centrul Medical Clubul Sănătăţii
Campulung Muscel, Romania
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.